C-Bond Systems, Inc.

C-Bond Systems, Inc., a nanotechnology company, owns, develops, manufactures, and sells patented C-Bond technology in the United Sates. The company's products include C-Bond NanoShield, a patented nanotechnology windshield glass strengthening and hydrophobic all-in-one performance system to improve windshield safety and performance; C-Bond Secure, a patented non-toxic water-based nanotechnology solution to improve the strength of architectural glass and performance properties of window film-to-glass products; and C-Bond BRS, a patented nanotechnology ballistic-resistant film system that increases the structural integrity of glass. It also distributes MB-10 and Vimoba disinfectant tablets to school facilities and buses, dealerships, global distribution network, and service providers, as well as the transportation detailing, automotive, trucking, RV, rental agency, service vehicles, mass transit, golf carts, aviation, train, and marine markets. The company was founded in 2013 and is headquartered in Houston, Texas.

C-Bond Systems, Inc. trades as CBNT on OTC. The company is classified in Basic Materials / Chemicals - Specialty and reports in USD.

The current profile places the business in Chemicals - Specialty. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.49M of revenue and $1.90M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

C-Bond Systems, Inc. can be compared against peers such as Blue Star Global, Inc., Global Gold Corporation, G6 Materials Corp., Hydromer, Inc., Hypower Fuel, Inc., Industrial Nanotech, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $536,672, beta of 0.26, and return on equity of -115.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CBNT currently shows total debt of $1.38M and beta of 0.26. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 15-12G (2025-04-07 00:00:00), 8-K (2025-03-06 00:00:00), 8-K (2025-02-04 00:00:00), 10-Q (2024-11-14 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.cbondsystems.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.